SCHEMBL1396385

SCHEMBL1396385

CCOC(=O)[C@H](CCCNC(N)=O)NC(=O)c1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCHE P06276 2/20 0.48
ACHE P22303 2/20 0.48
C3AR1 Q16581 1/20 0.48
CYP26A1 O43174 1/20 0.47
PADI1 Q9ULC6 4/20 0.47
PADI4 Q9UM07 4/20 0.47
PDE4A P27815 3/20 0.47
PADI2 Q9Y2J8 3/20 0.47
PADI3 Q9ULW8 3/20 0.47
PDE4B Q07343 2/20 0.47
PDE4C Q08493 2/20 0.47
PDE4D Q08499 2/20 0.47
PADI6 Q6TGC4 1/20 0.47
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
NAAA Q02083 1/20 0.44
GRIN1 Q05586 1/20 0.43
GRIN2A Q12879 1/20 0.43
CTSL P07711 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15271466 1.00 BCHE (0.48) BCHEACHEC3AR1CYP26A1PADI1
SCHEMBL24732379 0.91 NAAA (0.54) BCHEACHECYP26A1CA1CA2
SCHEMBL562113 0.91 BCHE (0.47) BCHEACHECYP26A1PADI1PADI4
SCHEMBL80453 0.91 BCHE (0.47) BCHEACHECYP26A1PADI1PADI4
SCHEMBL30925057 0.90 CA1 (0.56) C3AR1CYP26A1PADI1PADI4PDE4A
Hydrochloric Acid SCHEMBL538996 0.90 BCHE (0.46) BCHEACHECYP26A1PADI1PADI4
Hydrochloric Acid SCHEMBL11325263 0.90 BCHE (0.46) BCHEACHECYP26A1PADI1PADI4
SCHEMBL15739025 0.90 BCHE (0.46) BCHEACHECYP26A1PADI1PADI4
SCHEMBL15231556 0.84 C3AR1 (0.60) C3AR1PADI1PADI4PDE4APADI2
SCHEMBL7864695 0.84 ITGB3 (0.50) BCHEACHECYP26A1GRIN1GRIN2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8404647-B2 Peptidylarginine deiminase (PAD) inhibitors CHIRALIX B.V. (NL) 2013-03-26 US disclosed
EP-2288616-B1 PEPTIDYLARGININE DEIMINASE (PAD) INHIBITORS CHIRALIX B V (NL) 2012-11-21 EP disclosed
US-20110142868-A1 Peptidylarginine Deiminase (PAD) Inhibitors CHIRALIX B.V. (NL) 2011-06-16 US disclosed
EP-2288616-A1 PEPTIDYLARGININE DEIMINASE (PAD) INHIBITORS Chiralix B.V. (NL) 2011-03-02 EP disclosed
WO-2010005293-A1 PEPTIDYLARGININE DEIMINASE (PAD) INHIBITORS CHIRALIX B.V. (NL) 2010-01-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110142868-A1 Peptidylarginine Deiminase (PAD) Inhibitors PADI4, PADI2, PADI3 BCHE 375/4885ACHE 1070/4885C3AR1 1142/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.